UF Health experts interviewed for Breast Cancer Awareness Month

Karen Daily, D.O., provided a closer look at the importance of early detection and why it’s important to follow recommended screening guidelines. Read story.

In addition, Jennifer Fieber, M.D., was interviewed by WCJB TV20 about breast cancer screening and treatment. Watch interview.

New Clinical Trials Open for Enrollment

Nautilus: OKI-179 Plus Binimetinib in Patients with NRAS-mutated Melanoma

This Phase 2 trial is assessing the efficacy of oral OKI-179 combined with binimetinib in patients with advanced (unresectable Stage III/IV) NRAS-mutated melanoma previously treated with or ineligible for immune checkpoint inhibitors (ICI).  OKI-179 is a novel, selective, and orally available largazole-derived HDAC inhibitor. This trial will also assess efficacy, safety, and tolerability of this treatment combination.

Principal Investigator: Bently Doonan, M.D. 

A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer

This is a randomized, open-label, dose/schedule optimization study comparing NUC-3373/leucovorin (LV)/irinotecan plus bevacizumab (NUFIRI-bev)(NUC-3373 Q1 week versus Q2 weeks on a 28-day cycle) to 5-FU/LV/irinotecan plus bevacizumab (FOLFIRI-bev) for the treatment of patients with unresectable metastatic colorectal cancer.  The main objectives are to assess and compare the efficacy and safety of the 3 regimens. Pharmacokinetics will be assessed on the 2 NUFIRI arms.

Principal Investigator: Thomas George, M.D. 

NP-G2-044 in Combination with anti-PD-1 Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies

This is a Phase 2 trial of a novel fascin inhibitor (NP-G2-044) given in combination with standard of care anti-PD1 treatment, in solid tumor subjects with prior progression on anti-PD1 treatment. Subjects will received oral NP-G2-044, once daily on days 1-28 of a 28-day cycle, in addition to anti-PD1 therapy in accordance with the package insert.  Primary study objective is to assess preliminary anti-tumor efficacy of NP-G2-044 when administered in combination with anti-PD1 therapy. 

Principal Investigator: Thomas George, M.D. | Phase1@cancer.ufl.edu | 352-339-6672

AB-101 as Monotherapy and In Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Non-Hodgkins Lymphoma

This an open-label, Phase 1 / 2 trial is evaluating the safety and anti-tumor activity of AB-101 monotherapy or AB-101 in combination with Rituximab in patients with RR B-Cell NHL.  AB-101 is comprised of ex vivo-expanded allogeneic cord blood-derived natural killer (NK) cells cryopreserved in an infusion-ready suspension.  Treatment will involve a lymphodepleting regimen with Cyclophosphamide and Fludarabine, IL2, and AB 101 with or without Rituximab.  

Principal Investigator: Erin Dean, M.D.